Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

MLA

Daniel P. Petrylak, et al. “Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-Treated Patients with Advanced Urinary Tract Carcinoma.” European Urology Focus, vol. 7, no. 5, Sept. 2021, pp. 1084–91. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....57d4aed10e045e7ffc4e623722f971c1&authtype=sso&custid=ns315887.

APA

Daniel P. Petrylak, Robert Dreicer, Sabine de Ducla, Michiel S. van der Heijden, Jens Bedke, Jonathan E. Rosenberg, Thomas Powles, Yohann Loriot, Jose Luis Perez-Gracia, Simon Fear, Ernest Choy, Lars Thiebach, Axel S. Merseburger, Ignacio Duran, Cora N. Sternberg, Julie Pavlova, Daniel Castellano, & Jean H. Hoffman-Censits. (2021). Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. European Urology Focus, 7(5), 1084–1091.

Chicago

Daniel P. Petrylak, Robert Dreicer, Sabine de Ducla, Michiel S. van der Heijden, Jens Bedke, Jonathan E. Rosenberg, Thomas Powles, et al. 2021. “Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-Treated Patients with Advanced Urinary Tract Carcinoma.” European Urology Focus 7 (5): 1084–91. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....57d4aed10e045e7ffc4e623722f971c1&authtype=sso&custid=ns315887.